Third stage of the binding agreement of investment in and acquisition in stages of IOPtima

Tel Aviv (July 1st, 2019) – Further to BioLight’s announcement dated November 21, 2017, regarding signing a binding agreement for the investment in and the acquisition in stages of its subsidiary IOPtima Ltd. (“IOPtima”or the “Company”) (the “Agreement”) by the Chinese pharmaceutical company Chengdu Kanghong Pharmaceutical Group Co. (the “Acquirer”), and BioLight’s announcements dated March and September 2018 regarding completions of the first and second stages of the Agreement, BioLight hereby announces that the Acquirer  informed BioLight that it received all approvals required for the completion of the third stage of the Agreement.

Link to the complete article

Link to Newsroom

Comments are closed.